Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CANDESARTAN CILEXETIL
McDermott Laboratories Ltd t/a Gerard Laboratories
32 Milligram
Tablets
2011-08-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Candesartan Mylan 32mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 32 mg candesartan cilexetil. Each 32 mg tablet contains 148.0 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Candesartan cilexetil 32mg tablets are white to off white, round, biconvex tablet debossed with “M over C7” on one side and plain with a break line on the other side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension in adults. Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction 40%) as add-on therapy to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY IN HYPERTENSION The recommended initial dose and usual maintenance dose of Candesartan is 8mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16mg once daily and to a maximum of 32mg once daily. Therapy should be adjusted according to blood pressure response. Candesartan may also be administered with other antihypertensive agents. Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Candesartan. _Elderly Population_ No initial dosage adjustment is necessary in elderly patients. _Patients with intravascular volume depletion_ An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see also 4. Read the complete document